Molecular and Cell Biology Research Center (MCBRC), Hemoglobinopathy Institute, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Epidemiology, Gastrointestinal Cancer Research Center, Non-Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.
AIDS Res Hum Retroviruses. 2023 Jul;39(7):332-339. doi: 10.1089/AID.2022.0076. Epub 2023 Apr 21.
Epidemiological data demonstrate the greater severity of SARS-CoV-2 infection in HIV patients along with the more hospitalization, and mortality rates. Thus, this meta-analysis aimed to assess the possible differences in hospitalization, mortality, and the CD4 T cell counts between COVID-19/HIV co-infected patients and the control group. The relevant studies were obtained from online databases such as Science Direct, PubMed, Scopus, Web of Science, and Google Scholar using Mesh and Non-Mesh keywords and the meta-analysis was conducted according to the Preferred Reporting Items for Systematic review and Meta-Analysis Protocols checklist. Then, the Newcastle-Ottawa scale (NOS) checklist was used to assess the quality of selected studies. According to the random effect models, the odds ratios of hospitalization, mortality, and CD4 T cell counts were estimated. The odds ratios of hospitalization and mortality rates in COVID-19 patients with HIV were 1.67 (confidence interval [CI]: 0.76 to 3.71) and 0.80 (CI: 0.57 to 1.11), respectively, compared to that of the COVID-19 group. In this meta-analysis, there was no statistically significant difference in the rates of hospitalization, mortality, and CD4 T cell counts between COVID-19 patients with HIV and the control group. The similarity between the studied groups could be attributed to factors such as the rarity of COVID-19/HIV co-infection patients and the presence of random error, administration of antiretroviral therapy in HIV patients, and early hospitalization time in COVID-19/HIV co-infected patients.
流行病学数据表明,HIV 感染者感染 SARS-CoV-2 后病情更为严重,住院率和死亡率更高。因此,本荟萃分析旨在评估 COVID-19/HIV 合并感染患者与对照组在住院、死亡率和 CD4 T 细胞计数方面可能存在的差异。使用 Mesh 和非 Mesh 关键词从 Science Direct、PubMed、Scopus、Web of Science 和 Google Scholar 等在线数据库中获取相关研究,并根据系统评价和荟萃分析协议报告的首选项目清单进行荟萃分析。然后,使用纽卡斯尔-渥太华量表(NOS)检查表评估选定研究的质量。根据随机效应模型,估计住院、死亡率和 CD4 T 细胞计数的优势比。与 COVID-19 组相比,HIV 合并 COVID-19 患者的住院率和死亡率的优势比分别为 1.67(置信区间 [CI]:0.76 至 3.71)和 0.80(CI:0.57 至 1.11)。在本荟萃分析中,HIV 合并 COVID-19 患者与对照组在住院率、死亡率和 CD4 T 细胞计数方面无统计学差异。研究组之间的相似性可能归因于 COVID-19/HIV 合并感染患者的罕见性和随机误差的存在、HIV 患者接受抗逆转录病毒治疗以及 COVID-19/HIV 合并感染患者的早期住院时间等因素。